Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission: To promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
A position statement from the European Society of CardiologyWorking Groups on Cardiovascular Surgery and Valvular Heart Disease
Read the full text
Authors: Michele De Bonis, Nawwar Al-Attar, Manuel Antunes, Michael Borger, Filip Casselman, Volkmar Falk, Thierry Folliguet, Bernard Iung, Patrizio Lancellotti, Salvatore Lentini, Francesco Maisano, David Messika-Zeitoun, Claudio Muneretto, Phillipe Pibarot, Luc Pierard, Prakash Punjabi, Raphael Rosenhek, Piotr Suwalski, Alec Vahanian, Olaf Wendler, Bernard Prendergast
References: Eur Heart J (2014); DOI: http://dx.doi.org/10.1093/eurheartj/ehv322; First published online: 7 July 2015
Mitral regurgitation (MR) has a prevalence of 2% in the general population and is even more common in the elderly.1 Organic (or primary) MR arises as a result of pathology affecting one or more components of the mitral valve (MV) apparatus, whereas functional (or secondary) MR is a consequence of annular dilatation and geometrical distortion of the sub-valvular apparatus secondary to left ventricular (LV) remodelling and dyssynchrony, most usually associated with cardiomyopathy or coronary artery disease.
Primary MR is usually a consequence of degenerative disease, which may remain asymptomatic for many years—intervention has generally been withheld until the onset of symptoms or evidence of haemodynamic decompensation. However, treatment algorithms have been redefined in recent years as a result of the excellent outcomes of surgical repair. International guidelines now recommend risk stratification and earlier intervention when the probability of durable repair is high and when surgery can be undertaken by experienced teams with high repair rates and low operative mortality and morbidity.
Secondary MR has worse prognosis and treatment options are complex, including optimized medical therapy, biventricular pacing, valve surgery (with or without revascularization), long-term LV assist devices or cardiac transplantation. Surgery is challenging with inferior outcomes than in primary MR and the indications and choice of technique are not supported by robust evidence.
In recent years, a variety of approaches to percutaneous treatment of primary and secondary MR has emerged. The most widely adopted has been the edge-to-edge (EE) procedure with promising results in large registries and small randomized trials. Meanwhile, numerous alternative technologies (including percutaneous MV replacement) are in development.
Herein, a Task Force of the European Society of Cardiology (ESC) Working Groups on Cardiovascular Surgery and Valvular Heart Disease outline the indications and limitations of surgical and percutaneous treatment of MR, and propose recommendations for case selection, team working and outcome monitoring.
Joint paper with the WG on Cardiovascular Surgery
Read the full text
Authors: Miguel Sousa-Uva, Robert Storey, Kurt Huber, Volkmar Falk, Adeline Leite-Moreira, Julien Amour, Nawwar Al- Attar, Raimondo Ascione, David Taggart , and Jean-Philippe Collet
References: Eur Heart J (2014); doi: 10.1093/eurheartj/ehu158; First published online: April 18, 2014
Coronary artery bypass grafting (CABG)-related bleeding complications and perioperative coronary events are strongly influenced by the management of antithrombotic therapy before and after CABG. Bleeding but also blood products transfusion increase the risk of death and compromise the long-term benefits of CABG.1 The use of new P2Y12 inhibitors, increasing pre-CABG percutaneous coronary interventions (PCI) with drug eluting stents (DES) requiring specific antiplatelet regimens, and advances in surgical technique has prompted the ESC Working Group on Cardiovascular Surgery and the ESC Working Group on Thrombosis to review the evidence of peri-CABG recommendations on antithrombotic management. Due to the paucity of randomized trials, most of the evidence is still derived from observational studies and expert consensus, further reinforcing the importance of a multidisciplinary consultation for optimal decision making.